This post hoc analysis of the SPIRIT-H2H study showed that patients with PsA that were treated with ixekizumab had significantly higher rates of symptom resolution versus adalimumab at Weeks 12 and 52 in distal interphalangeal joint disease and nail PsO.

September 2023

Three-year data from the ixekizumab (IXE) COAST programme provide additional evidence that patients with axSpA receiving IXE experience long-term safety, and sustained improvements in efficacy outcomes, at 3 years.

Post-hoc analysis of SPIRIT-P1 and SPIRIT-P2 concludes that ixekizumab (IXE) is effective in improving axial symptoms in patients with active PsA presenting with axial manifestations.

December 2022

In this study ixekizumab and secukinumab patients had similar treatment patterns. It was also surmised that the use of adjunctive pain and anti-inflammatory medications were similar between therapies. In coming to this conclusion investigators aimed to compare treatment patterns and use of pain and anti-inflammatory medications between patients with PsA initiating ixekizumab and secukinumab in two cohorts of patients from…(add here where is the population coming from).

Keywords:

October 2022

In this latest investigation into ixekizumab more patients achieved targets assessed by mCPDAI and DAPSA than with other composites. This study assess’ the concordance and variability in performance of the composite measures in patients with PsA, as well as to provide greater granularity to the frequency and severity of residual symptoms in patients who achieve treatment targets.

The present analysis demonstrated that patients continuously treated with IXE were less likely to experience flare compared with patients receiving placebo. The aim of this study was to evaluate the recapture of response with open-label IXE retreatment at week 104 in patients with axSpA who flared after withdrawal of IXE therapy.

September 2022

This study highlighted improvements in disease activity, function and quality of life were achieved early on into treatment and were sustained through 116 weeks of IXE therapy for patients with r-axSpA and nr-axSpA. In this study investigators aimed to report the long-term efficacy and safety results for patients treated with ixekizumab for up to 116 weeks.

June 2022

van der Horst-Bruinsma et al., carried out a post-hoc analysis to confirm that the clinical presentations and responses to ixekizumab therapy may differ in male and female patients.

Maksymowych et al., evaluated the efficacy of Ixekizumab in patients with radiographic axial spondyloarthritis (r-axSpA) with and without objective measures of inflammation.

May 2022

This analysis aimed to report the safety profile of ixekizumab for the PsA SPIRIT programme. The overall safety profile and tolerability of ixekizumab are consistent with the previously known safety profile in patients with PsA.